FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
- FDA 近 90 天出现 31 次
- 上一次：同一天稍早 · Former White House economist: science has delivered a cancer detection revolution, now the FDA must keep pace
发生了什么
The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.
摘要按规则整理自下方来源原文